H.C. Wainwright analyst Yi Chen downgraded Tourmaline Bio (TRML) to Neutral from Buy with a price target of $48, down from $50, after the company entered into a merger agreement to be acquired by Novartis (NVS) for $48 per share in cash or $1.4B. The firm does not expect a competitive bid to emerge at this time.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Hold from Buy at Truist
- Tourmaline Bio downgraded to Neutral from Buy at Chardan
- Tourmaline Bio downgraded to Hold from Buy at Jefferies
- Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
- Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital